PDE2 and PDE10, but not PDE5, inhibition affect basic auditory information processing in rats

Behavioural Brain Research

Volumn 250, Issue , 2013, Pages 251-256

  Reneerkens, O A H ^a,b   Sambeth, A ^a,b   Blokland, A ^a,b   Prickaerts, J ^a,b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b European Graduate School of Neuroscience   (Netherlands)

Author keywords

Auditory information processing; PDE10; PDE2; PDE5; Schizophrenia; Sensory gating

Indexed keywords

BAY 60 7550; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V; PHOSPHODIESTERASE X; PQ 10; SPLEEN EXONUCLEASE; UNCLASSIFIED DRUG; VARDENAFIL;

ANIMAL EXPERIMENT; ARTICLE; AUDITORY INFORMATION PROCESSING; AUDITORY STIMULATION; BRAIN FUNCTION; BRAIN REGION; BRAIN VERTEX; COGNITION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG MECHANISM; DRUG TARGETING; ELECTROENCEPHALOGRAM; ENZYME INHIBITION; ENZYME SPECIFICITY; HIPPOCAMPUS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SENSORY GATING; STIMULUS RESPONSE;

EID: 84878916949     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.05.014     Document Type: Article

References (60)

1. Blokland A., Menniti F.S., Prickaerts J. PDE inhibition and cognition enhancement. Expert Opinion on Therapeutic Patents 2012, 22:349-354.
2. Reneerkens O.A., Rutten K., Steinbusch H.W., Blokland A., Prickaerts J. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology (Berl) 2009, 202:419-443.
3. Prickaerts J., Sik A., van Staveren W.C., Koopmans G., Steinbusch H.W., van der Staay F.J., et al. Phosphodiesterase type 5 inhibition improves early memory consolidation of object information. Neurochemistry International 2004, 45:915-928.
4. Puzzo D., Staniszewski A., Deng S.X., Privitera L., Leznik E., Liu S., et al. Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer's disease mouse model. Journal of Neuroscience 2009, 29:8075-8086.
5. Cuadrado-Tejedor M., Hervias I., Ricobaraza A., Puerta E., Perez-Roldan J.M., Garcia-Barroso C., et al. Sildenafil restores cognitive function without affecting beta-amyloid burden in a mouse model of Alzheimer's disease. British Journal of Pharmacology 2011, 164:2029-2041.
6. Reneerkens O.A., Rutten K., Akkerman S., Blokland A., Shaffer C.L., Menniti F.S., et al. Phosphodiesterase type 5 (PDE5) inhibition improves object recognition memory: indications for central and peripheral mechanisms. Neurobiology of Learning and Memory 2012, 97:370-379.
7. Patil C.S., Jain N.K., Singh V.P., Kulkarni S.K. Differential effect of the PDE5 inhibitors, sildenafil and zaprinast, in aging - and lippolysaccharide-induced cognitive dysfunction in mice. Drug Development Research 2004, 63:66-75.
8. Devan B.D., Bowker J.L., Duffy K.B., Bharati I.S., Jimenez M., Sierra-Mercado D., et al. Phosphodiesterase inhibition by sildenafil citrate attenuates a maze learning impairment in rats induced by nitric oxide synthase inhibition. Psychopharmacology (Berl) 2006, 183:439-445.
9. Rutten K., Basile J.L., Prickaerts J., Blokland A., Vivian J.A. Selective PDE inhibitors rolipram and sildenafil improve object retrieval performance in adult cynomolgus macaques. Psychopharmacology (Berl) 2008, 196:643-648.
10. Reneerkens O., Sambeth A., Ramaekers J., Steinbusch H., Blokland A., Prickaerts J. The effects of the phosphodiesterase type 5 inhibitor vardenafil on cognitive performance in healthy adults: a behavioral-electroencephalography study. Journal of Psychopharmacology 2013, 10.1177/0269881113477747.
11. Grass H., Klotz T., Fathian-Sabet B., Berghaus G., Engelmann U., Kaferstein H. Sildenafil (Viagra): is there an influence on psychological performance?. International Urology and Nephrology 2001, 32:409-412.
12. Schultheiss D., Muller S.V., Nager W., Stief C.G., Schlote N., Jonas U., et al. Central effects of sildenafil (Viagra) on auditory selective attention and verbal recognition memory in humans: a study with event-related brain potentials. World Journal of Urology 2001, 19:46-50.
13. Shim Y.S., Pae C.U., Kim S.W., Kim H.W., Kim J.C., Koh J.S. Effects of repeated dosing with Udenafil (Zydena) on cognition, somatization and erection in patients with erectile dysfunction: a pilot study. International Journal of Impotence Research 2011, 23:109-114.
14. Boess F.G., Hendrix M., van der Staay F.J., Erb C., Schreiber R., van Staveren W., et al. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology 2004, 47:1081-1092.
15. van Donkelaar E.L., Rutten K., Blokland A., Akkerman S., Steinbusch H.W., Prickaerts J. Phosphodiesterase 2 and 5 inhibition attenuates the object memory deficit induced by acute tryptophan depletion. European Journal of Pharmacology 2008, 600:98-104.
16. Domek-Lopacinska K., Strosznajder J.B. The effect of selective inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and 5 on learning and memory processes and nitric oxide synthase activity in brain during aging. Brain Research 2008, 1216:68-77.
17. Rutten K., Prickaerts J., Hendrix M., van der Staay F.J., Sik A., Blokland A. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors. European Journal of Pharmacology 2007, 558:107-112.
18. Sierksma A.S., Rutten K., Sydlik S., Rostamian S., Steinbusch H.W., van den Hove D.L., et al. Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease. Neuropharmacology 2012, 64:124-136.
19. Rodefer J.S., Saland S.K., Eckrich S.J. Selective phosphodiesterase inhibitors improve performance on the ED/ID cognitive task in rats. Neuropharmacology 2012, 62:1182-1190.
20. Smith S.M., Uslaner J.M., Cox C.D., Huszar S.L., Cannon C.E., Vardigan J.D., et al. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey. Neuropharmacology 2013, 64:215-223.
21. Reneerkens O.A., Rutten K., Bollen E., Hage T., Blokland A., Steinbusch H.W., et al. Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801. Behavioural Brain Research 2012, 236C:16-22.
22. Grauer S.M., Pulito V.L., Navarra R.L., Kelly M.P., Kelley C., Graf R., et al. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. Journal of Pharmacology and Experimental Therapeutics 2009, 331:574-590.
23. Hebb A.L., Robertson H.A., Denovan-Wright E.M. Phosphodiesterase 10A inhibition is associated with locomotor and cognitive deficits and increased anxiety in mice. European Neuropsychopharmacology 2008, 18:339-363.
24. Lakics V., Karran E.H., Boess F.G. Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology 2010, 59:367-374.
25. van Staveren W.C., Steinbusch H.W., Markerink-van Ittersum M., Behrends S., de Vente J. Species differences in the localization of cGMP-producing and NO-responsive elements in the mouse and rat hippocampus using cGMP immunocytochemistry. The European Journal of Neuroscience 2004, 19:2155-2168.
26. Van Staveren W.C., Steinbusch H.W., Markerink-Van Ittersum M., Repaske D.R., Goy M.F., Kotera J., et al. mRNA expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain. The Journal of Comparative Neurology 2003, 467:566-580.
27. Stephenson D.T., Coskran T.M., Kelly M.P., Kleiman R.J., Morton D., O'Neill S.M., et al. The distribution of phosphodiesterase 2A in the rat brain. Neuroscience 2012, 226:145-155.
28. Loughney K., Hill T.R., Florio V.A., Uher L., Rosman G.J., Wolda S.L., et al. Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase. Gene 1998, 216:139-147.
29. Fujishige K., Kotera J., Michibata H., Yuasa K., Takebayashi S., Okumura K., et al. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). The Journal of Biological Chemistry 1999, 274:18438-18445.
30. Loughney K., Snyder P.B., Uher L., Rosman G.J., Ferguson K., Florio V.A. Isolation and characterization of PDE10A, a novel human 3',5'-cyclic nucleotide phosphodiesterase. Gene 1999, 234:109-117.
31. Soderling S.H., Bayuga S.J., Beavo J.A. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:7071-7076.
32. Xu Y., Zhang H.T., O'Donnell J.M. Phosphodiesterases in the central nervous system: implications in mood and cognitive disorders. Handbook of Experimental Pharmacology 2011, 447-485.
33. Schmidt C.J., Chapin D.S., Cianfrogna J., Corman M.L., Hajos M., Harms J.F., et al. Preclinical characterization of selective PDE10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. Journal of Pharmacology and Experimental Therapeutics 2008, 325:681-690.
34. Cromwell H.C., Mears R.P., Wan L., Boutros N.N. Sensory gating: a translational effort from basic to clinical science. Clinincal EEG and Neuroscience 2008, 39:69-72.
35. Halene T.B., Siegel S.J. Antipsychotic-like properties of PDE4 inhibitors - evaluation of RO-20-1724 with auditory event related potentials and prepulse inhibition of startle. Journal of Pharmacology and Experimental Therapy 2008, 326:230-239.
36. Adler L.E., Pachtman E., Franks R.D., Pecevich M., Waldo M.C., Freedman R. Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biological Psychiatry 1982, 17:639-654.
37. Javitt D.C. Sensory processing in schizophrenia: neither simple nor intact. Schizophrenia Bulletin 2009, 35:1059-1064.
38. Jessen F., Kucharski C., Fries T., Papassotiropoulos A., Hoenig K., Maier W., et al. Sensory gating deficit expressed by a disturbed suppression of the P50 event-related potential in patients with Alzheimer's disease. American Journal of Psychiatry 2001, 158:1319-1321.
39. Chang W.P., Arfken C.L., Sangal M.P., Boutros N.N. Probing the relative contribution of the first and second responses to sensory gating indices: a meta-analysis. Psychophysiology 2011, 48:980-992.
40. Dalecki A., Croft R.J., Johnstone S.J. An evaluation of P50 paired-click methodologies. Psychophysiology 2011, 48:1692-1700.
41. Boutros N.N., Brockhaus-Dumke A., Gjini K., Vedeniapin A., Elfakhani M., Burroughs S., et al. Sensory-gating deficit of the N100 mid-latency auditory evoked potential in medicated schizophrenia patients. Schizophrenia Research 2009, 113:339-346.
42. Lijffijt M., Moeller F.G., Boutros N.N., Burroughs S., Lane S.D., Steinberg J.L., et al. The role of age, gender, education, and intelligence in P50, N100, and P200 auditory sensory gating. Journal of Psychophysiology 2009, 23:52-62.
43. Broberg B.V., Oranje B., Glenthoj B.Y., Fejgin K., Plath N., Bastlund J.F. Assessment of auditory sensory processing in a neurodevelopmental animal model of schizophrenia - gating of auditory-evoked potentials and prepulse inhibition. Behavioural Brain Research 2010, 213:142-147.
44. Mears R.P., Boutros N.N., Cromwell H.C. Reduction of prelimbic inhibitory gating of auditory evoked potentials after fear conditioning. Behavioral Neuroscience 2009, 123:315-327.
45. Mears R.P., Klein A.C., Cromwell H.C. Auditory inhibitory gating in medial prefrontal cortex: single unit and local field potential analysis. Neuroscience 2006, 141:47-65.
46. Zhou D., Ma Y., Liu N., Chen L., He M., Miao Y. Influence of physical parameters of sound on the sensory gating effects of N40 in rats. Neuroscience Letters 2008, 432:100-104.
47. Miyazato H., Skinner R.D., Garcia-Rill E. Neurochemical modulation of the P13 midlatency auditory evoked potential in the rat. Neuroscience 1999, 92:911-920.
48. Reneerkens O.A., Sambeth A., Van Duinen M.A., Blokland A., Steinbusch H.W., Prickaerts J. The PDE5 inhibitor vardenafil does not affect auditory sensory gating in rats and humans. Psychopharmacology 2013, 225(2):303-312.
49. Boess F.G., De Vry J., Erb C., Flessner T., Hendrix M., Luithle J., et al. The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents. Journal of Pharmacology and Experimental Therapeutics 2007, 321:716-725.
50. Bickford-Wimer P.C., Nagamoto H., Johnson R., Adler L.E., Egan M., Rose G.M., et al. Auditory sensory gating in hippocampal neurons: a model system in the rat. Biological Psychiatry 1990, 27:183-192.
51. Cromwell H.C., Klein A., Mears R.P. Single unit and population responses during inhibitory gating of striatal activity in freely moving rats. Neuroscience 2007, 146:69-85.
52. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1998, Academic Press, London. 4th ed.
53. Singh N., Parle M. Sildenafil improves acquisition and retention of memory in mice. Indian Journal of Physiology and Pharmacology 2003, 47:318-324.
54. Devan B.D., Pistell P.J., Daffin L.W., Nelson C.M., Duffy K.B., Bowker J.L., et al. Sildenafil citrate attenuates a complex maze impairment induced by intracerebroventricular infusion of the NOS inhibitor N(omega)-nitro-l-arginine methyl ester. European Journal of Pharmacology 2007, 563:134-140.
55. Devan B.D., Sierra-Mercado D., Jimenez M., Bowker J.L., Duffy K.B., Spangler E.L., et al. Phosphodiesterase inhibition by sildenafil citrate attenuates the learning impairment induced by blockade of cholinergic muscarinic receptors in rats. Pharmacology Biochemistry and Behaviour 2004, 79:691-699.
56. Baratti C.M., Boccia M.M. Effects of sildenafil on long-term retention of an inhibitory avoidance response in mice. Behavioural Pharmacology 1999, 10:731-737.
57. Siuciak J.A. The role of phosphodiesterases in schizophrenia: therapeutic implications. CNS Drugs 2008, 22:983-993.
58. Alderton W., Karran E., Ward S. Current and future perspectives in psychiatric drug discovery. Drug News & Perspectives 2009, 22:360-364.
59. Bender A.T., Beavo J.A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacological Reviews 2006, 58:488-520.
60. Maxwell C.R., Kanes S.J., Abel T., Siegel S.J. Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications. Neuroscience 2004, 129:101-107.